1. Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c 
Matthew A. Cavender, MD, MPH, Benjamin M. Scirica, MD, MPH, Itamar Raz, MD, Ph. Gabriel Steg, MD, Darren K. McGuire, MD, MHSc, Lawrence A. Leiter, MD, Boaz Hirshberg, MD, Jaime Davidson, MD, Avivit Cahn, MD, Ofri Mosenzon, MD, KyungAh Im, PhD, Eugene Braunwald, MD, Deepak L. Bhatt, MD, MPH 
The American Journal of Medicine 
Volume 129, Issue 3, Pages 340.e1-340.e8 (March 2016)
DOI: /j.amjmed
Copyright © 2016 Elsevier Inc. Terms and Conditions

2. Figure 1
Baseline hemoglobin A1c and the risk of cardiovascular death, myocardial infarction, or ischemic stroke.
The American Journal of Medicine  , 340.e1-340.e8DOI: ( /j.amjmed )
Copyright © 2016 Elsevier Inc. Terms and Conditions

3. Figure 2
Association of baseline hemoglobin A1c with cardiovascular events.
The American Journal of Medicine  , 340.e1-340.e8DOI: ( /j.amjmed )
Copyright © 2016 Elsevier Inc. Terms and Conditions

4. Figure 3
Primary and secondary efficacy endpoints by baseline hemoglobin A1c in patients treated with saxagliptin or placebo.
The American Journal of Medicine  , 340.e1-340.e8DOI: ( /j.amjmed )
Copyright © 2016 Elsevier Inc. Terms and Conditions